QUEBEC CITY, Nov. 15 /CNW Telbec/ - Atrium Innovations Inc., "Atrium" (TSX: ATB), is pleased to announce that following an American court decision, the Company has received approval to sell its enzyme supplement Wobenzym(R) N in the United States. Marlyn Nutraceuticals, Inc. "Marlyn", located in Phoenix, Arizona, has been ordered by the U.S. District Court to immediately stop using the Wobenzym(R) N trademark and selling products under this name.
Wobenzym(R) N was initially developed more than 40 years ago by Mucos Pharma GmbH & Co "Mucos", a company acquired by Atrium in July 2007. Wobenzym(R) N is an enzyme-based product well known within the medical community in Germany and certain Eastern European countries for its numerous benefits for the health of joints, muscles and tendons as well as for the immune system. As one of the top selling joint and muscle health products in these countries, annual sales of Wobenzym(R) N by Mucos currently stand at over US$90 million.
"We are very pleased with this court ruling, which will allow us to start selling Wobenzym(R) N in the United States immediately and with no restrictions," stated Pierre Fitzgibbon, President and Chief Executive Officer of Atrium Innovations. "This high-quality product, sold as an enzyme supplement in the U.S., offers a natural solution to very common conditions such as joint and muscle discomfort. Through our two American subsidiaries, Douglas Laboratories and Pure Encapsulations, which serve some 40,000 healthcare professionals in the U.S., we have gained in-depth knowledge of this market, and this edge will allow us to rapidly commercialize Wobenzym(R) N. We also intend to draw on other specialized distribution networks that offer strong business potential. This decision signifies a major development for Atrium and will allow the Company to accelerate its growth and development in the United States."
For more information on Wobenzym(R) N, please visit our Web site at www.wobenzym-usa.com
Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets, which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 600 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com.
Cautionary Note and Forward-Looking Statements
This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.